NCT04073615View on ClinicalTrials.gov

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Rivoceranib

Film-coated tablets

DRUG

Trifluridine/Tipiracil

Film-coated tablets

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

37232

Vanderbilt University School of Medicine, Nashville

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
lead

Elevar Therapeutics

INDUSTRY

NCT04073615 - A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter